1812 related articles for article (PubMed ID: 30156747)
61. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
Shaefer CF; Kushner P; Aguilar R
Postgrad Med; 2015; 127(8):818-26. PubMed ID: 26371721
[TBL] [Abstract][Full Text] [Related]
62. Albiglutide for the management of type 2 diabetes.
Rendell MS
Expert Rev Endocrinol Metab; 2018 Jan; 13(1):1-8. PubMed ID: 30063441
[TBL] [Abstract][Full Text] [Related]
63. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.
Gallwitz B
Drugs; 2011 Sep; 71(13):1675-88. PubMed ID: 21902291
[TBL] [Abstract][Full Text] [Related]
64. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
Johansen P; Hunt B; Iyer NN; Dang-Tan T; Pollock RF
Adv Ther; 2019 May; 36(5):1190-1199. PubMed ID: 30875029
[TBL] [Abstract][Full Text] [Related]
65. Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study.
Otto T; Myland M; Jung H; Lebrec J; Richter H; Norrbacka K
Curr Med Res Opin; 2019 May; 35(5):893-901. PubMed ID: 30328731
[TBL] [Abstract][Full Text] [Related]
66. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
Bettge K; Kahle M; Abd El Aziz MS; Meier JJ; Nauck MA
Diabetes Obes Metab; 2017 Mar; 19(3):336-347. PubMed ID: 27860132
[TBL] [Abstract][Full Text] [Related]
67. Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy.
Bzowyckyj A
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):7-16. PubMed ID: 32910488
[TBL] [Abstract][Full Text] [Related]
68. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity.
Maselli DB; Camilleri M
Adv Exp Med Biol; 2021; 1307():171-192. PubMed ID: 32077010
[TBL] [Abstract][Full Text] [Related]
69. [Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].
Li ZX; Wu SS; Yang ZR; Zhan SY; Sun F
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Jun; 48(3):454-9. PubMed ID: 27318907
[TBL] [Abstract][Full Text] [Related]
70. Albiglutide: a unique GLP-1 receptor agonist.
Rendell MS
Expert Opin Biol Ther; 2016 Dec; 16(12):1557-1569. PubMed ID: 27677385
[TBL] [Abstract][Full Text] [Related]
71. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.
Terauchi Y; Satoi Y; Takeuchi M; Imaoka T
Endocr J; 2014; 61(10):949-59. PubMed ID: 25029955
[TBL] [Abstract][Full Text] [Related]
72. Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials.
Zhang YS; Weng WY; Xie BC; Meng Y; Hao YH; Liang YM; Zhou ZK
Osteoporos Int; 2018 Dec; 29(12):2639-2644. PubMed ID: 30083774
[TBL] [Abstract][Full Text] [Related]
73. Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis.
Zaccardi F; Htike ZZ; Webb DR; Khunti K; Davies MJ
Ann Intern Med; 2016 Jan; 164(2):102-13. PubMed ID: 26642233
[TBL] [Abstract][Full Text] [Related]
74. GLP-1 receptor agonists and cardiovascular outcome trials: An update.
Andrikou E; Tsioufis C; Andrikou I; Leontsinis I; Tousoulis D; Papanas N
Hellenic J Cardiol; 2019; 60(6):347-351. PubMed ID: 30528435
[TBL] [Abstract][Full Text] [Related]
75. DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.
Wang W; Wen X; Duan W; Wang X; Chen Y; Dong J; Yang Z; Fang J; Zhou Z; Yao G; Fang Y; Huang Y
J Endocrinol Invest; 2020 May; 43(5):653-662. PubMed ID: 31786794
[TBL] [Abstract][Full Text] [Related]
76. The efficacy and safety of exenatide once weekly in patients with type 2 diabetes.
Heimbürger SM; Brønden A; Johansen NJ; Dejgaard TF; Vilsbøll T; Knop FK
Expert Opin Pharmacother; 2019 Apr; 20(5):501-510. PubMed ID: 30730773
[TBL] [Abstract][Full Text] [Related]
77. Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists.
Madsbad S; Holst JJ
Cardiovasc Res; 2023 May; 119(4):886-904. PubMed ID: 35925683
[TBL] [Abstract][Full Text] [Related]
78. Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus.
Harris KB; Boland CL
Pharmacotherapy; 2016 Sep; 36(9):1011-20. PubMed ID: 27485823
[TBL] [Abstract][Full Text] [Related]
79. Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).
Kimura T; Katakura Y; Shimoda M; Kawasaki F; Yamabe M; Tatsumi F; Matsuki M; Iwamoto Y; Anno T; Fushimi Y; Kamei S; Kimura Y; Nakanishi S; Mune T; Kaku K; Kaneto H;
Diabetes Obes Metab; 2023 Dec; 25(12):3632-3647. PubMed ID: 37646192
[TBL] [Abstract][Full Text] [Related]
80. Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy.
Boye KS; Matza LS; Stewart KD; Jordan J; Biricolti G; Del Santo S; Perez-Nieves M; Federici MO; Gentilella R; Losi S; Norrbacka K
J Med Econ; 2019 Aug; 22(8):806-813. PubMed ID: 31010349
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
